2171061-85-9
2171061-85-9
Chemical Structure
Nidanilimab (Nadunolimab)
Synonym(s): CAN04; Anti-IL-1RAP/IL-1R3 Reference Antibody (nidanilimab)
- CAS No.: 2171061-85-9
- Formula:N/A
- Molecular Weight:(144.3 kDa)
IUPAC Name: N-methyl-3-phenyl-3-(4-(trifluoromethyl)phenoxy-2,3,5,6-d4)propan-1-amine oxalate
SMILES: [Nidanilimab (Nadunolimab)]
Biological Activity: Nidanilimab (CAN04) is a fully humanized monoclonal anti-IL1RAP antibody with a Kd value of 1.10 pM. Nidanilimab blocks IL1α and IL1β signaling and stimulates the immune system to destroy tumour cells. Nidanilimab can be used in research of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) [1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Nidanilimab (Nadunolimab) | 99.9% | Nidanilimab (CAN04) is a fully humanized monoclonal anti-IL1RAP antibody with a Kd value of 1.10 pM. Nidanilimab blocks IL1α and IL1β signaling and stimulates the immune system to destroy tumour cells. Nidanilimab can be used in research of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) . | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Millrud CR, et, al. The anti-IL1RAP antibody CAN04 increases tumor sensitivity to platinum-based chemotherapy.
- [2]. Rydberg Millrud C, et, al. Blockade of IL-1α and IL-1β signaling by the anti-IL1RAP antibody nadunolimab (CAN04) mediates synergistic anti-tumor efficacy with chemotherapy. Cancer Immunol Immunother. 2022 Aug 29. [Content Brief]
